Role of MMP-1 1G/2G Promoter Gene Polymorphism on the Development of Prostate Cancer in the Turkish Population

Albayrak, Selami; Cangüven, Önder; Göktaş, Cemal; Aydemi̇r, Hüseyi̇n; Köksal, Vedat

doi:10.1159/000109715

Cited by 22 publications

(26 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is only one small-scale study regarding prostate cancer, which showed that the MMP-1 promoter polymorphism was not associated with susceptibility to the disease (29). Our relatively large-scale study also did not find any association with susceptibility to prostate cancer.…”

Section: Discussioncontrasting

confidence: 77%

“…In prostate cancer, immunohistochemical and in situ hybridization analysis have detected MMP-1 in cancer cells as well as in normal adjacent and prostatic intraepithelial cells (28). However, a previous study that evaluated the effect of the polymorphism on prostate cancer found no association between MMP-1 and susceptibility or metastatic status of prostate cancer (29). There have been few studies focusing on the clinical implication of MMP-1 expression, promoter polymorphism, and allelic imbalance (AI) of 11q22.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer

Tsuchiya

Narita²,

Kumazawa³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Matrix metalloproteinase-1 (MMP-1) is associated with cancer invasion and metastasis. The 2G allele of the polymorphic site in the MMP-1 promoter was demonstrated to have a higher transcription activity than the 1G allele. Allelic imbalance (AI) at 11q22 harboring the MMP-1 is frequently observed in various cancers and may be associated with an advanced disease. We conducted a case-control study to determine the association of the MMP-1 genotype with susceptibility to prostate cancer involving 283 prostate cancer patients and 251 controls. Furthermore, AI, retention allele of the MMP-1 promoter, and MMP-1 protein expression were analyzed in 77 prostate cancer specimens. The MMP-1 promoter polymorphism was associated with neither susceptibility nor progression of prostate cancer. Tumors with 1G/2G and 2G/2G genotypes had a significantly higher MMP-1 expression level compared to those with 1G/1G genotype (P=0.006 and 0.013, respectively). AI at 11q22 was observed in 13 (40.6%) of 32 informative cases. Retention of the 1G and 2G alleles were observed in 4 and 9 cases, respectively. AI was significantly associated with the Gleason score (P=0.003) and pathological stage (P=0.022). In addition, retention of the 2G allele showed a significant association with the pathological stage (P=0.026). AI at 11q22 region, retention of the 2G allele, specifically appeared to be involved in the progression of prostate cancer. However, the presence of the 2G allele of the MMP-1 promoter polymorphism itself seems to influence neither the susceptibility nor the progression of prostate cancer. IntroductionTumor invasion or metastasis is one of the most crucial events for determining the outcome of cancer patients. In the first step of these events, several proteinases such as serine proteinase urokinase plasminogen activator and matrix metalloproteinases (MMPs) degrade the extra-cellular matrix (ECM), so that the tumor cells can migrate to the stromal tissue through the basement membrane (1). MMP-1, a member of MMP family, is abundantly expressed in many types of cancer cells and adjacent stromal fibroblasts (2-5), and digests various elements of the ECM including collagen types I, II, II, VII, VIII, X, and XI (6). The overexpression of MMP-1 has been shown to be associated with tumor progression and poor outcomes for cancers of the digestive system and melanoma (3,5,7,8).The expression of MMP-1 is mainly regulated by activated protein-1 (AP-1) transcription factor that mediates signal transduction from cytokines and growth factors such as interferons, interleukins, epidermal growth factor, and fibroblast growth factor (9). In the promoter region of the MMP-1, three AP-1 binding sites are located at -72, -186, and -1062 bp from the transcription start site. Insertion of an extra guanine residue adjacent to the AP-1 binding site at -1062 bp creates a new binding site for ETS transcription factor at -1602 bp (5'-AAGGAT-3'; 2G), and both the AP-1 and ETS cooperatively enhance the expression of MMP-1 (10). AP-1 binding to the -1...

show abstract

Section: Discussioncontrasting

confidence: 77%

Section: Introductionmentioning

confidence: 99%

Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer

Tsuchiya

Narita²,

Kumazawa³

et al. 2009

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…There were eight articles, including 1689 cancer cases and 1690 controls, for the MMP1 -1607 1G/2G SNP (four about bladder cancer, two about prostate cancer, and two about renal cell carcinoma); four articles, including 1020 cancer cases and 960 controls, for the MMP2 -1306 C/T SNP; three articles, including 838 cancer cases and 735 controls, for the MMP9 -1562 C/T SNP; two articles, including 440 cancer cases and 399 controls, for the MMP7 -181 A/G SNP; three articles, including 907 cancer cases and 942 controls, for the MMP9 (279R/Q) A/G SNP; two articles, including 726 cancer cases and 737 controls, for the MMP3 (45E/K) G/A SNP; two articles, including 756 cancer cases and 760 controls, for the MMP9 (574R/P) T/C SNP; and two articles, including 745 cancer cases and 745 controls, for the MMP9 (668Q/R) A/G SNP. The distribution of genotypes among the control samples was consistent with HWE in all studies except four: Kader et al (2006), Albayrak et al (2007), Srivastava et al (2010b), and Wieczorek et al (2013). Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), DNA sequencing, and TaqMan Ò Real-Time PCR were used as genotyping methods in all publications.…”

Section: Eligible Studiesmentioning

confidence: 84%

“…We also found only one Chinese article in the WanFang database. As a result, 12 case-control articles were included in our meta-analysis: (Hirata et al, 2004;Zhong et al, 2005;Kader et al, 2006;Albayrak et al, 2007;Piccoli et al, 2007;Tasci et al, 2008;Tsuchiya et al, 2009;Srivastava et al, 2010aSrivastava et al, , 2010bWieczorek et al, 2013Wieczorek et al, , 2014Srivastava et al, 2013a) (Fig. 1).…”

Section: Eligible Studiesmentioning

confidence: 99%

“…A quantitative synthesis to accumulate data from different studies is needed to provide better evidence on these associations. Here, in this report, we performed a meta-analysis of 12 publications to estimate the effect of eight polymorphisms: MMP1 -1607 1G/2G (Hirata et al, 2004;Kader et al, 2006;Albayrak et al, 2007;Piccoli et al, 2007;Tasci et al, 2008;Tsuchiya et al, 2009;Srivastava et al, 2010a;Wieczorek et al, 2013), MMP2 -1306 C/T (Zhong et al, 2005;Kader et al, 2006;Srivastava et al, 2013a;Wieczorek et al, 2013), MMP3 (45E/K) G/A (Kader et al, 2006;Srivastava et al, 2010b), MMP7 -181 A/G (Srivastava et al, 2010a;Wieczorek et al, 2014), MMP9 -1562 C/T (Zhong et al, 2005;Kader et al, 2006;Wieczorek et al, 2013), MMP9 (279R/Q) A/G (Kader et al, 2006;Tasci et al, 2008;Srivastava et al, 2010b), and MMP9 (574R/P) T/C (Kader et al, 2006;Srivastava et al, 2010b), MMP9 (668Q/R) A/G (Kader et al, 2006;Srivastava et al, 2010b) on urinary cancer risk.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MMP1, 2, 3, 7, and 9 Gene Polymorphisms and Urinary Cancer Risk: A Meta-Analysis

Liu

Zuo

et al. 2015

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

Background: The matrix metalloproteinases (MMPs) are a family of highly conserved, metal-dependent proteolytic enzymes that play an important role in tumor invasion and metastasis. Many studies have been carried out on the association between polymorphisms in the MMP1, MMP2, MMP3, MMP7, and MMP9 genes and urinary cancer risk. However, the data from these published studies are conflicting and have low statistical power. Methods: In this study, we performed a meta-analysis of 12 different publications from the PubMed and WanFang databases, published up to May 2015, to better assess the purported associations. Odds ratios (OR) and 95% confidence intervals (CI) were determined to reveal association strengths. Results: Some significant associations were found. For the MMP1 -1607 1G/2G polymorphism, a negative association was identified for the 2G allele in bladder cancer (2G2G+2G1G vs. 1G1G: OR = 0.57, 95% CI = 0.36-0.93, p heterogeneity = 0.001) and renal cell carcinoma (2G1G vs. 1G1G: OR = 0.57, 95% CI = 0.39-0.82, p heterogeneity = 0.567). For the MMP2 -1306 C/T polymorphism, there was a negative association with the T allele for bladder cancer in the Asian population (TT+TC vs. CC: OR = 0.41, 95% CI = 0.18-0.94, p heterogeneity = 0.195). For the MMP7 -181 A/G polymorphism, a decreased bladder cancer risk was found (G-allele vs. A-allele: OR = 0.81, 95% CI = 0.66-0.98, p heterogeneity = 0.325). Conclusion: In summary, our study showed evidence that genetic polymorphisms in MMP1 for all populations, but only in the Asian population for MMP2 and MMP7, may protect against bladder cancer risk. Future studies with larger sample sizes are warranted to further evaluate these associations in more detail.

show abstract

Pharmacogenetics of Angiogenesis

Bocci¹,

Pasqualetti²,

Paolo³

et al. 2010

Drug Management of Prostate Cancer

View full text Add to dashboard Cite

Angiogenesis is a complex cascade of events involving extensive interplay between cells, soluble factors, and extracellular matrix components. Soluble factors including cytokines and growth factors have multifaceted stimulatory or inhibitory roles, thereby finely tuning the process. The angiogenic potential of tumors was initially demonstrated in animal models, and it is now recognized that angiogenesis not only precedes tumor growth but is also necessary for metastasis. Vascular endothelial growth factor (VEGF) plays a central role in prostate angiogenesis. Genetic variability of VEGF involves mainly the untranslated region of the gene and may be associated with increased VEGF transcription and protein expression. Indeed, the -1154G>A polymorphism increases VEGF transcription and has been associated with significantly increased risk of prostate cancer. Hypoxia inducible factor-1a (HIF-1a) is a transcription factor overexpressed in early stage prostate cancer; through its binding to hypoxic responsive elements, it activates the transcription of a wide variety of genes as a part of the cellular response to hypoxia, including VEGF, and potentially plays a key role in prostate cancer development and response to antiangiogenic drugs. Therefore, angiogenesis-related genes seem to have an important role in prostate cancer risk and aggressiveness, thus influencing the outcome of antiangiogenic treatments and survival of patients

show abstract

Role of MMP-1 1G/2G Promoter Gene Polymorphism on the Development of Prostate Cancer in the Turkish Population

Cited by 22 publications

References 21 publications

Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer

Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer

MMP1, 2, 3, 7, and 9 Gene Polymorphisms and Urinary Cancer Risk: A Meta-Analysis

Pharmacogenetics of Angiogenesis

Contact Info

Product

Resources

About